

AWARD NUMBER: W81XWH-13-1-0257

TITLE: Coregulation of srGAP1 by Wnt and Androgen Receptor Signaling: A New Target for Treatment of CRPC

PRINCIPAL INVESTIGATOR: Noriko Yokoyama

CONTRACTING ORGANIZATION: University of California, Irvine  
Irvine, CA 92617-3067

REPORT DATE: October 2014

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                 |                                  |                                                | Form Approved<br>OMB No. 0704-0188             |                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|----------------------------------|------------------------------------------------|------------------------------------------------|--------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                 |                                  |                                                |                                                |                                            |
| 1. REPORT DATE<br>October 2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                 | 2. REPORT TYPE<br>Annual         |                                                | 3. DATES COVERED<br>15 Sept 2013- 14 Sept 2014 |                                            |
| 4. TITLE AND SUBTITLE<br><br>Coregulation of srGAP1 by Wnt and Androgen Receptor Signaling: A New Target for Treatment of CRPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                 |                                  |                                                | 5a. CONTRACT NUMBER                            |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 5b. GRANT NUMBER<br>W81XWH-13-1-0257           |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 5c. PROGRAM ELEMENT NUMBER                     |                                            |
| 6. AUTHOR(S)<br>Noriko Yokoyama<br><br>E-Mail: nyokoyam@uci.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 5d. PROJECT NUMBER                             |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 5e. TASK NUMBER                                |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 5f. WORK UNIT NUMBER                           |                                            |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>UNIVERSITY OF CALIFORNIA, Irvine<br><br>IRVINE CA 92617-3067                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                 |                                  |                                                | 8. PERFORMING ORGANIZATION REPORT NUMBER       |                                            |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                 |                                  |                                                | 10. SPONSOR/MONITOR'S ACRONYM(S)               |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  |                                                | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)         |                                            |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                 |                                  |                                                |                                                |                                            |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                 |                                  |                                                |                                                |                                            |
| 14. ABSTRACT<br>Androgen receptor (AR) and Wnt signaling both play a critical role during prostate cancer progression to castration-resistance prostate cancer (CRPC). Over expression of AR can activate transcriptional activities of Wnt signaling pathway and promote CRPC. Recent data in our laboratory showed a potential co-regulation of srGAP1 (Slit-Robo-GTPase activating protein1) and active Wnt and AR signaling in CRPC. srGAP1 is a downstream component of Slit-Robo signaling. Our data showed that srGAP1 is overexpressed in CRPC cell lines (androgen-insensitive prostate cancer) while absent in both androgen-sensitive cells and in normal prostate epithelial cells. We also detected increased srGAP1 and LEF-1 expression in human CRPC tissues compared with normal epithelial prostate and androgen sensitive prostate cancer tissues by immunohistochemistry analysis. When androgen-sensitive LNCaP cells were grown under androgen deprived condition, we observed induced expression of srGAP1. Interestingly, srGAP1 expression was also increased when LNCaP cells were grown under Wnt stimulated conditions. And, srGAP1 expression was decreased when Wnt signaling was inhibited by a Wnt antagonist Wnt-inhibitory factor-1 (WIF-1) in CRPC cell lines. Chromatin immunoprecipitation assay was performed to examine whether Wnt transcription factor TCF-4 binds to the srGAP1 promoter. Overexpression of WIF-1 inhibited the promoter activity of srGAP1. Taken together, our results indicated that srGAP1 is co-regulated by both Wnt and AR signaling and srGAP1 may be a new potential Wnt target gene in castration-resistance prostate cancer. |                                 |                                  |                                                |                                                |                                            |
| 15. SUBJECT TERMS<br>CRPC, AR, srGAP, Robo1, Wnt, WIF1, GTPases, LEF-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                 |                                  |                                                |                                                |                                            |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |                                  | 17. LIMITATION OF ABSTRACT<br><br>Unclassified | 18. NUMBER OF PAGES<br><br>34                  | 19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC |
| a. REPORT<br><br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | b. ABSTRACT<br><br>Unclassified | c. THIS PAGE<br><br>Unclassified |                                                |                                                | 19b. TELEPHONE NUMBER (include area code)  |

## Table of Contents

|                                                    | <u>Page</u> |
|----------------------------------------------------|-------------|
| 1. Introduction.....                               | 4           |
| 2. Keywords.....                                   | 4           |
| 3. Overall Project Summary.....                    | 4 – 10      |
| 4. Key Research Accomplishments.....               | 10          |
| 5. Conclusion.....                                 | 10          |
| 6. Publications, Abstract, and Presentations. .... | 11          |
| 7. Inventions, Patents, and Licenses.....          | 11          |
| 8. Reportable Outcomes.....                        | 11          |
| 9. Other Achievements.....                         | 11          |
| 10. Appendices.....                                | 11 – 33     |
| i. CV.....                                         | 12 – 16     |
| ii. Published manuscript.....                      | 17 – 34     |

## 1. INTRODUCTION:

Prostate cancer is one of the most common cancer diagnosed in the United States and advanced staged prostate cancer especially patients who develop resistance to androgen deprivation therapy, known as castration-resistance prostate cancer (CRPC), is one of the leading causes of death in males. In the recent years, researchers have discovered that androgen receptor (AR) and Wnt signaling both play a critical role during prostate cancer progression to CRPC. Over expression of AR can activate transcriptional activities of Wnt signaling pathway and promote CRPC. Our laboratory discovered a potential co-regulation of srGAP1 (Slit-Robo-GTPase activating protein1) and active Wnt and AR signaling in CRPC cell lines. srGAP1 is a downstream component of Slit-Robo signaling. Our data showed that srGAP1 is overexpressed in CRPC cell lines (22Rv1, C4-2B, PC3, PC3M, PC3/LN4) while absent in both androgen-sensitive cells and in normal prostate epithelial cells. Aside from our study there are no other reports linking srGAP1 and prostate cancer. In this report we summarize new studies and findings of srGAP1 in prostate cancer and linking Wnt and the Slit-Robo signaling pathway through identification of srGAP1 as a Wnt target. Our goal is to identify srGAP1 and Slit-Robo pathway as a new target and develop a novel treatment for CRPC.

## 2. KEYWORDS:

CRPC, AR, srGAP, Robo1, Wnt, WIF1, GTPases, LEF-1


## 3. OVERALL PROJECT SUMMARY:

**Summary of annual progress is addressed in this section.**

**Specific Aim 1:** *Test the hypothesis that srGAP1 is a target gene of Wnt signaling and regulated by AR signaling in CRPC.* Chromatin Immunoprecipitation (ChIP) assays will be carried out to examine LEF-1 binding to Wnt response element on the 5' promoter region of srGAP1 gene. Luciferase reporter assay will be used to examine whether 5' promoter Wnt response element is functional and can be activated by Wnt signaling. Immunohistochemistry will be performed to examine co-expression of srGAP1, LEF1, and AR in human prostate cancer tissues. The transcription regulation of srGAP1 in prostate cancer cells will be studied under Wnt and androgen stimulated conditions. Wnt antagonists and androgen deprivations will be used for inhibiting conditions.

### **Specific Aim1 progress**

1) There are three potential LEF/TCF transcription factor binding sites approximately 2.8kb upstream of srGAP1 coding region (Figure 1A). All LEF/TCF transcription factors can recognize and bind to the same consensus sequence YCTTTGWW. We performed Chromatin Immunoprecipitation (ChIP) to examine whether TCF4 transcription factor can bind to 5' promoter region of SRGAP1 gene. ChIP assay was performed using CRPC cell lines PC3 whether endogenous TCF-4 binds to the SRGAP1 promoter. Primer set that detects all three LEF/TCF binding of the 5' promoter region of SRGAP1 was used to perform PCR and real time PCR. We observed that TCF-4 binds to the SRGAP1 promoter (Figure 1B). We also performed ChIP assay using PC3 stable cells that overexpresses Wnt inhibitors WIF-1 and Frzb. TCF-4 binds to the SRGAP1 promoter in the absence of Wnt inhibitors, whereas, TCF-4 occupancy was decreased in the presence of Wnt inhibitors (Figure 1C). ChIP data strongly suggests that srGAP1 expression is regulated by Wnt signaling.




2) We performed immunohistochemistry to examine srGAP1 expression in human prostate cancer tissues for both androgen sensitive PCa and CRPC. We detected significantly more srGAP1 expressed in CRPC tumor tissues compared to androgen sensitive PCa tissues (Figure 2A). We also performed immunohistochemistry to examine LEF-1 expression as well. LEF-1 is also significantly more expressed in CRPC tumor tissues compared to androgen sensitive PCa (Figure 2B).


**Figure 2.**  
**srGAP1 and LEF-1 are highly expressed in CRPC tumor tissues.**

**A)** Immunohistochemistry staining of srGAP1 in androgen sensitive PCa and CRPC tissues. Average staining scores of srGAP1 shown in graph.

**B)** Immunohistochemistry staining of LEF1 in androgen sensitive PCa and CRPC tissues. Average staining scores of LEF1 shown in graph.



3) We next looked to compare expression patterns for srGAP1 and LEF-1 expression in LNCaP (androgen sensitive PCa), LNCaP-AI (a derivative of LNCaP cells from long term androgen deprivation), and LNCaP-LEF1 (LNCaP cells overexpressing LEF-1). Protein expression shown by Western blot analysis show that LEF-1 transcription factor have higher expression in androgen-insensitive prostate cancer (LNCaP-AI and LNCaP-LEF1) compared to androgen sensitive prostate cancer (LNCaP) (Figure 3A). We also looked at protein and RNA expression pattern of srGAP1 in androgen sensitive PCa cells grown under androgen deprivation conditions (Figure 3B). LNCaP cells were cultured under 10% cFBS condition for seven days. At the last 24 hours, synthetic androgen (R1881) were added different concentrations. Both Western and real-time PCR result show that different androgen levels in the medium can regulate srGAP1 expression. Furthermore, we looked at srGAP1 expression levels in PC3 and C4-2B (androgen insensitive) cells overexpressing Wnt inhibitors WIF1 and Frzb (Figure 3C). We detected significant reduction of srGAP1 expression in both protein and RNA levels which indicates that Wnt signaling is involved in controlling expression levels of srGAP1 in CRPC.



**Specific Aim2:** Test the hypothesis that down regulating srGAP1 in CRPC cells change phenotypic characteristics and reverse tumorigenesis and metastasis. We will stably or transiently knockdown srGAP1 expression in CRPC cells using shRNA and examine the effect of srGAP1 on cell growth, migration and invasion. In addition, perform intra-prostatic (orthotopic) implantation of CRPC cell line C4-2B with or without suppression of srGAP1 and examine tumor growth and metastasis in SCID mice.


### Specific Aim2 progress

1) We used lentivirus shRNA knockdown method to stably knockdown srGAP1 expression in PC3 (CRPC) cell lines. Figure 4A shows Western blot analysis of srGAP1 protein expression of PC3 cells knockdown with control shRNA and srGAP1 shRNA. We observed significant morphological changes (data not shown) when srGAP1 was knocked-down.

2) Cell proliferation assay (also known as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) Assay) was conducted with both control shRNA and srGAP1 shRNA to compare for cell viability and proliferation during 72hrs of cell growth. srGAP1 knockdown cells inhibited cell growth by about 50% compared to the native PC3 and shCtrl-PC3 cells during 72 hrs growth period.

3) Preliminary migration and matrigel invasion assay was conducted to examine PC3-shCtrl and PC3-shsrGAP1 cells ability to migrate and invade across Matrigel. Cell motility was tested by PC3-shCtrl and shsrGAP1 PC3 cells ability to migrate through membrane chamber after 24hrs. *In vitro* invasiveness of PC3-shCtrl and shsrGAP1 PC3 cells were tested by how efficiently the cells invade through a Matrigel-coated membrane after 48hrs. Consistent with our migration data we observed a decrease in invasive capacity of srGAP1 knocked-down cells compared to the control cells (Fig 4C). We have only conducted experiment once, therefore, we would have to repeat the experiment few more times to conclude that srGAP1 knockdown inhibit cell invasion in CRPC cells.





**Figure 4. Knockdown of srGAP1 by shRNA induces significant morphological changes leading to inhibition of cell growth and migration in PC3 cells.**

**A)** Western blot analysis of srGAP1 protein expression of PC3 cells stably transfected with scrambled control shRNA and srGAP1 shRNA.

**B)** PC3 cells with knockdown control shRNA and srGAP1 shRNA were grown for three days for cell viability assay. Cell viability was measured by the MTT assay.

**C)** shCtrl and shsrGAP1 knockdown cells were examined for cell motility by using migration membrane chambers and Matrigel-coated invasion chambers. Number of migrated cells were counted and percent of shsrGAP1 cells were compared over shCtrl PC3 cells.

4) To prepare for the up coming *in vivo* mouse model study I have completed all the mouse handling and surgery training through UCI's ULAR program. IRB and IACUC protocols are all approved for this project as well.

#### **4. KEY RESEARCH ACCOMPLISHMENTS:**

- With Western blot and immunohistochemistry we showed that srGAP1 is highly expressed in androgen-insensitive prostate cancer in both cancer cell lines and tumor tissues.
- With androgen deprivation study with Western blot and reverse transcriptase followed by realtime PCR study showed that Wnt signaling is involved in controlling expression levels of srGAP1 in androgen insensitive prostate cancer.
- We detected high LEF-1 transcription factors expression in androgen-insensitive prostate cancer (LNCaP-AI and LNCaP-LEF1) compared to androgen sensitive prostate cancer (LNCaP).
- Chromatin immunoprecipitation study showed that downstream Wnt transcription factor, TCF-4, binds to *SRGAP1* promoter, therefore, srGAP1 expression is regulated by Wnt signaling.
- srGAP1 knockdown studies showed that cells with little to no srGAP1 expression reduces and slows down the growth of PC3 (CRPC) cells.
- Finally, we observed that PC3 srGAP1 knockdown cells decreases migration and potentially invasion compared to the control PC3 cells.
- In summary, these above results suggest that srGAP1 may play an important role in cellular function of CRPC cells.

#### **5. CONCLUSION:**

From the above research in progress section we have shown that srGAP1 plays an important role in regulation in cellular function of CRPC cells. Moreover, cross-talk between the Wnt and Slit-Robo signaling have not been previously known, our data uncovers that both Wnt and Slit-Robo signaling may be regulating srGAP1 in CRPC cells. In the next few months we will begin our *in vivo* mouse study of CRPC cells by injecting PC3-control and PC3-shsrGAP1 in mice. Tumor growth will be monitored and compared between the two groups. Once the tumor is enlarged we will sacrifice the mice and observe for metastasis by collecting samples for pathology, RNA extraction, and protein lysates. Finally, our up-to-date research indicates that SrGAP1 may be a good target for therapeutic intervention of CRPC. srGAP1 is an enzyme (Rho GTPase), therefore, it may be a good candidate for generating new pharmaceutical compounds to target this protein for drug screening.

## **6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:**

1) Manuscript published

Yokoyama, N.N., Shao, S., Hoang, B.H., Mercola, D., Zi, X. 2014. Wnt signaling in castration-resistant prostate cancer: implications for therapy. *Am J Clin Exp Urol.* Apr;2(1):27-44.

2) Abstract submission at AACR April 2013 conference.

Yokoyama, N.N., Sakai, T., Sun, Z., Shao, S., Huang, J., Hoang, B.H., and Zi, X. Co-regulation of srGAP1 by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference 2014, San Diego, CA

## **7. INVENTIONS, PATENTS AND LICENSES:**

Nothing to report

## **8. REPORTABLE OUTCOMES:**

Nothing to report

## **9. OTHER ACHIEVEMENTS:**

Nothing to report

## **10. APPENDICES:**

## *Curriculum Vitae*

**Noriko N Yokoyama**

E-mail Address:      nyokoyam@uci.edu

### **Education:**

|           |                                                                                 |
|-----------|---------------------------------------------------------------------------------|
| 1997-2001 | University of Texas at Austin<br>Bachelor of Science in Molecular biology       |
| 2001-2003 | University of California, Irvine<br>Master of Science in Biotechnology          |
| 2003-2009 | University of California, Irvine<br>Doctor of Philosophy in Biological Sciences |

### **Research Experience:**

|           |                                                                                                                                                            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1996      | Student Research with Annette Fothergill, Pathology Department of Fungus Testing Lab.<br>University of Texas Health Science Center San Antonio, Texas      |
| 2000-2001 | Undergraduate Research with Professor Paul J. Szaniszlo Ph.D.,<br>Department of Microbiology<br>University of Texas at Austin                              |
| 2001-2003 | Masters graduate research with Professor Michael Cumsy Ph.D.,<br>Department of Molecular Biology and Biochemistry<br>University of California, Irvine      |
| 2002-2003 | Associate Intern at Allergan Pharmaceuticals with Peter Baciou Ph.D.,<br>Research and Development, Department of Biology<br>Irvine, California             |
| 2003      | Predoctoral Graduate Research with Professor David Camerini Ph.D.,<br>Department of Molecular Biology and Biochemistry<br>University of California, Irvine |

- 2004-2009      Predoctoral Graduate Research with Professor Marian L. Waterman Ph.D.,  
Department of Microbiology and Molecular Genetics  
University of California, Irvine
- 2009-2010      Junior Specialist with Professor Marian L. Waterman Ph.D.,  
Department of Microbiology and Molecular Genetics  
University of California, Irvine
- 2012-Present    Postdoctoral fellow with Professor Xiaolin Zi Ph.D., MD,  
Department of Urology  
University of California Irvine Medical Center, Orange

**Teaching Experience:**

- 2003              Teaching Assistant, Genetic engineering/Biotechnology (Mol Bio 228),  
University of California, Irvine
- 2003-2004      Teaching Assistant, Biotech Nucleic acid (Mol Bio 250L) and Biotech  
Protein (Mol Bio 251L), Laboratory, University of California, Irvine
- 2007              Grading assistant, Regulation of Gene Expression (Mol Bio 206),  
University of California, Irvine

**Academic-Related Service and Fellowship awards:**

- 2003-2004      MBGB (Molecular Biology, Genetics, and Biochemistry) Fellowship,  
University of California, Irvine
- 2005-2006      Student Representative, Department of Microbiology and Molecular  
Genetics, University of California, Irvine
- 2007              Dr. William F. Holcomb Scholarship for outstanding research in  
Biomedical Science
- 2007-2008      NIH Training grant entitled “Translational Research in Cancer Genomic  
Medicine”
- 2013              Awarded DOD Prostate Cancer Research Program Postdoctoral Training  
grant (W81XWH-13-1-0257, 09/15/2013-08/31/2015)  
Title of the project “Co-regulation of srGAP1 by Wnt and androgen  
receptor signaling: a new target for treatment of castration resistant  
prostate cancer”

## **Professional membership**

2012-2014     American Association for Cancer Research (AACR)

## **Patent:**

2004            "Mouse cell lines for CCR5, CCR7". University of California Invention.  
UC Case No: 2004-273. Camerini, D., Yeh, Y., Yokoyama, N.N., and de  
Armes, L.R. Issued 2004.

## **Seminar Presentations:**

- 2004   Yokoyama, N.N. Activation and Repression of *LEF1* Promoters in Colon Cancer.  
Gene Expression seminar series, University of California, Irvine
- 2006   Yokoyama, N.N. *LEF1* gene regulation and expression in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of  
California, Irvine
- 2007   Yokoyama, N.N. Repression of the *LEF1* Alternative Promoter in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of  
California, Irvine
- 2008   Yokoyama, N.N. Repression of the *LEF1* Alternative Promoter in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of  
California, Irvine
- 2009   Yokoyama, N.N. Repression of the *LEF1* Alternative Promoter in Colon cancer.  
Doctoral thesis defense, University of California, Irvine
- 2013   Guest Speaker for the RCP (Research Careers Prep) Program  
Cal State Fullerton (CSUF)

## **Poster Presentations:**

- 2001   Yokoyama, N.N., Liu, H., Starvrou, I., and Szaniszlo P.J. Constructing Double  
Disruption Mutants of *WdCHS*, a Gene that Encodes Chitin Synthase in  
*Wangiella dermatitidis*. Undergraduate research presentation, University of Texas  
at Austin
- 2004   Yokoyama, N.N., Li, T. W.-H., and Waterman, M.L. Activation and Repression  
of *LEF1* Promoters in Colon Cancer. Microbiology & Molecular Genetics  
Departmental Research Retreat, Lake Arrowhead, CA

- 2005 Yokoyama, N.N., Li, T. W.-H., and Waterman, M.L. Activation and Repression of *LEF1* Promoters in Colon Cancer. BSDB meeting, Wnt signaling in Development, Disease, and Cell Biology, Aberdeen, University of Aberdeen
- 2006 Yokoyama, N.N., Li, T. W.-H., Ting, J.-H. T., and Waterman, M.L. Repression of the *LEF1* Alternative Promoter in Colon Cancer. Keystone Symposia, Wnt and Beta-Catenin Signaling in Development and Disease, Snowbird Resort, Snowbird Utah
- 2006 Yokoyama, N.N., and Waterman, M.L. Repression of the *LEF1* Alternative Promoter in Colon Cancer. Microbiology & Molecular Genetics Departmental Research Retreat, Lake Arrowhead, CA
- 2007 Yokoyama, N.N., Li, T. W.-H., Pate, K., Ko, A., Ranheim, E., and Waterman, M.L. Repression of the *LEF1* Alternative Promoter in Colon Cancer. WNT conference. University of California, San Diego. La Jolla, CA
- 2007 Yokoyama, N.N., Li, T. W.-H., Pate, K., Ko, A., Ranheim, E., and Waterman, M.L. Repression of the *LEF1* Alternative Promoter in Colon Cancer. Wnt Signaling in Development and Disease. Max Delbruck Center for Molecular Medicine, Berlin-Buch, Germany
- 2013 Yokoyama, N.N., Sun, Z., Sakai, T., Hoang, B. H., and Zi, X. Robo1, a new target, is regulated by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference, Washington D.C.
- 2014 Yokoyama, N.N., Sakai, T., Sun, Z., Shao, S., Huang, J., Hoang, B.H., and Zi, X. Co-regulation of srGAP1 by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference, San Diego, CA

### **Publications:**

- Ye, Y., De Leon, J., **Yokoyama, N.**, Naidu, Y., and Camerini, D. 2005. DBR1 siRNA inhibition of HIV-1 replication, *Retrovirology* Oct 18:2:53.
- Li, T. W.-H., Ting, J.-H. T., **Yokoyama, N.N.**, Bernstein, A., van de Wetering, M., and Waterman, M.L. 2006. Wnt Activation and Alternative Promoter Repression of *LEF1* in Colon Cancer, *Molecular and Cellular Biology* July;26(14):5284-5299.
- Arce, L., **Yokoyama N.N.** and Waterman M.L. 2006. Diversity of the LEF/TCF's in Development and Disease, *Oncogene* Dec 4;25(57):7492-504.
- Atcha, A.A., Syed, A., Wu, B., Hoverter, N., **Yokoyama N.N.**, Ting, J-H. T., Munguia, J.E., Mangalam, H.J., Marsh, J.L., and Waterman M.L. 2007. Inclusion of a second DNA binding domain by alternative splicing converts TCF-1 and TCF-4

into stronger Wnt effectors, *Molecular and Cellular Biology*. Dec;27(23):8352-8363.

**Yokoyama, N.N.**, Pate, K.T., Sprowl, S., and Waterman, M.L. 2010. A role for YY1 in repression of dominant negative LEF-1 expression in colon cancer, *Nucleic Acids Research*. Oct;38(19):6375-88.

**Yokoyama, N.N.**, Shao, S., Hoang, B.H., Mercola, D., Zi, X. 2014. Wnt signaling in castration-resistant prostate cancer: implications for therapy. *Am J Clin Exp Urol*. Apr;2(1):27-44.



## Review Article

# Wnt signaling in castration-resistant prostate cancer: implications for therapy

Noriko N Yokoyama<sup>1</sup>, Shujuan Shao<sup>1</sup>, Bang H Hoang<sup>2</sup>, Dan Mercola<sup>4,5,6</sup>, Xiaolin Zi<sup>1,2,3,4</sup>

Departments of <sup>1</sup>Urology, <sup>2</sup>Pharmaceutical Sciences, <sup>3</sup>Pharmacology, <sup>4</sup>Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA; <sup>5</sup>Department of Othopeadic Surgery, University of California, Irvine, Orange, CA 92868, USA; <sup>6</sup>Department of Pathology and Laboratory Medicine, University of California, Irvine, Orange, CA 92868, USA

Received March 9, 2014; Accepted March 26, 2014; Epub April 5, 2014; Published April 15, 2014

**Abstract:** Increasing evidence has indicated that Wnt signaling plays complex roles in castration resistant prostate cancer (CRPC). Although not all data were consistent,  $\beta$ -catenin nuclear localization and its co-localization with androgen receptor (AR) were more frequently observed in CRPC compared to hormone naïve prostate cancer. This direct interaction between AR and  $\beta$ -catenin seemed to elicit a specific expression of a set of target genes in low androgen conditions in CRPC. Paracrine Wnt signaling also was shown to aid resistance to chemotherapy and androgen deprivation therapy. Results from the next generation sequencing studies (i.e. RNA-seq and whole exosome sequencing) of CRPC specimens have identified the Wnt pathway as one of the top signaling pathways with significant genomic alterations in CRPC, whereas, Wnt pathway alterations were virtually absent in hormone naïve primary prostate cancer. Furthermore, Wnt signaling has been suggested to play an important role in cancer stem cell functions in prostate cancer recurrence and resistance to androgen deprivation therapy. Therefore, in this review we have summarized existing knowledge regarding potential roles of Wnt signaling in CRPC and underline Wnt signaling as a potential therapeutic target for CRPC. Further understanding of Wnt signaling in castration resistance may eventually contribute new insights into possible treatment options for this incurable disease.

**Keywords:** Wnt signaling, castration-resistant prostate cancer, targeted therapy

## Introduction

Prostate cancer is a biologically diverse disease. A significant proportion of elderly men with this disease are asymptomatic [1, 2]. Most of these asymptomatic cases are prostate cancers which may be managed by watchful waiting and active surveillance. Prostate cancer patients who have clinically localized disease at diagnosis often receive curative treatments through radical prostatectomy or radiotherapy. However, between 20% and 40% of these patients eventually experience biochemical recurrence [3, 4]. Patients with biochemically recurrent disease, metastatic prostate cancer, and locally advanced prostate cancer are then mainly treated with androgen deprivation therapy (ADT). Since the 1940s, ADT consists of surgical or medical castration method to reduce circulating androgens [5]. Unfortunately, all patients eventually develop resistance to ADT

called castration-resistant prostate cancer (CRPC) [6]. Recently, two new FDA approved drugs (i.e. Abiraterone Acetate and Enzalutamide) more effectively block androgen synthesis and to prevent activation of androgen receptor (AR) [7, 8]. Although these AR targeting agents extend life of CRPC patients by a few months, resistance to these treatments remains common and currently there is no cure for CRPC [9-18]. Therefore, understanding the molecular mechanisms leading to CRPC and identifying alternative targets are important in developing more effective treatment for CRPC.

Much new evidence summarized here indicates that the Wnt signaling pathway is one of the major pathways that are involved in developing CRPC. The Wnt pathway plays a central role in the development of many tissues and organs [19]. Aberrant activation of the Wnt/ $\beta$ -catenin pathway contributes to the progression of sev-

**Table 1.** Proposed mechanisms for elevated Wnt signaling in CRPC

| Mechanisms                                                            | References       |
|-----------------------------------------------------------------------|------------------|
| Nuclear $\beta$ -catenin localization                                 | [32, 41]         |
| AR/ $\beta$ -catenin interaction                                      | [26, 32, 35, 68] |
| LEF1 overexpression                                                   | [83]             |
| Crosstalk between $\beta$ -catenin and AKT, HIF-1 $\alpha$ and others | [69-75]          |
| Overexpression of Wnt ligands and receptors                           | [23, 94-106]     |
| Paracrine Wnt signaling                                               | [36, 37, 91-93]  |
| Loss of secreted Wnt antagonists                                      | [136]            |
| Epithelial to mesenchymal transition                                  | [123, 124, 137]  |
| Cancer stem cells                                                     | [134]            |

eral major human cancers, including colorectal, liver and prostate cancer [19]. Evidence has accumulated that the Wnt/ $\beta$ -catenin pathway plays an important role in CRPC by interacting with AR signaling [20-33]. Recent studies using next-generation sequencing of CRPC tumors have revealed significant genomic alterations in multiple components of the Wnt pathway, whereas, alterations of the Wnt pathway in hormone treatment naïve prostate cancer were vitually undetectable [34, 35]. Moreover, it has been reported that aberrant paracrine Wnt signaling from prostatic stroma can also contribute to the resistance to ADT before or after chemotherapy [36, 37]. Hence, the main goal of this review is to summarize the important role of the Wnt/ $\beta$ -catenin in progression to CRPC and discuss potential therapeutic approaches for targeting the Wnt pathway for treatment of CRPC. Proposed mechanisms for elevated Wnt signaling in CRPC are summarized in **Table 1**.

#### Nuclear $\beta$ -catenin expression in CRPC

The Wnt (wingless-type) signaling transduction pathway has three different pathways, the canonical Wnt/ $\beta$ -catenin, non-canonical planar cell polarity, and the non-canonical Wnt/Calcium pathway; essentially separating but interacting pathways (**Figure 1**) [19, 38, 39]. The best-studied Wnt signaling pathway is the canonical Wnt/ $\beta$ -catenin pathway in which Wnt ligands form a complex with Frizzled (FZD) receptor and coreceptors such as the low-density lipoprotein receptor-related protein 5 (LRP5) or LRP6. Upon receptor activation, the “destruction complex” which includes adenomatous polyposis coli (APC) protein and Axin is inhibited thereby blocking the phosphorylation of  $\beta$ -catenin by both casein kinase I $\alpha$  and glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ). Phosphorylation of  $\beta$ -catenin normally targets  $\beta$ -catenin

for degradation. This inhibition results in cytoplasmic  $\beta$ -catenin stabilization and accumulation which facilitates its translocation into the nucleus. Nuclear  $\beta$ -catenin acts as a transcriptional coactivator and interacts with transcriptions factors such as T-cell factor (TCF) and lymphoid enhancer factor (LEF) and leads to increased transcription of target genes, such as MMP7, c-Myc, cyclin

D1, c-Jun, Fra and other members of the c-Fos family. In addition, Wnt signaling can also regulate other noncanonical pathways such as the JNK pathway independent of  $\beta$ -catenin leading to changes in cell polarity, movement, and survival [19, 38, 39].

$\beta$ -Catenin is a dual function protein and it can regulate cell-cell adhesion and gene activation [33]. A hallmark of canonical Wnt signaling is the stabilization and nuclear localization of  $\beta$ -catenin [19]. Therefore, various groups have studied  $\beta$ -catenin localization in CRPC specimens compared to hormone-naïve prostate cancer (**Table 2**). Chesire et al. [40] reported that about 24% (5/21) of metastatic tumors from various anatomical sites of autopsy samples from CRPC patients were positive for  $\beta$ -catenin nuclear localization. de la Taille et al. [41] evaluated  $\beta$ -catenin expression by immunohistochemistry staining in 212 prostate cancer specimens, including 122 localized prostate cancer from prostatectomy specimens and 90 from CRPC specimens from transurethral resections of the prostate due to bladder obstruction. Abnormal  $\beta$ -catenin expression was defined as cytoplasmic and/or nuclear staining. In this study, about 23% of radical prostatectomy specimens exhibited abnormal  $\beta$ -catenin expression compared to 38.8% of metastatic CRPC cases with statistically significant result of  $p = 0.042$ . Likewise, Patriarca et al. [42] found that  $\beta$ -catenin levels were also elevated in 20 acinar prostatic adenocarcinomas after anti-androgen therapy in prostatectomy specimens compared to that of pretreatment biopsies of the same patient group and high Gleason grade, matched and untreated controls. Wan et al. [32] also found nuclear localization of  $\beta$ -catenin in 11 of 27 (40.7%)

**Table 2.** Nuclear  $\beta$ -catenin localization in CRPC and hormone naïve prostate cancer

| Sources                        | Percentage of positive staining      | References |
|--------------------------------|--------------------------------------|------------|
| Metastatic tumors from autopsy | 24% (5/21), nuclear                  | [40]       |
| CRPC from TURP                 | 38.8% (35/90), nuclear               | [41]       |
| CRPC bone metastases           | 40.7% (11/27), nuclear               | [43]       |
| CRPC matched pairs             | 55% (16/29), nuclear and cytoplasmic | [35]       |
| Localized PCa from RP          | 23% (49/212), nuclear                | [41]       |
| Localized PCa from RP          | 18% (39/186), nuclear                | [50]       |

PCa: prostate cancer; RP: radical prostatectomy; CRPC: castration resistant prostate cancer; TURP: transurethral resections of the prostate.


CRPC bone metastases. Eight (29.6%) of 27 specimens exhibited both  $\beta$ -catenin and androgen receptor positive staining in the nuclei compared to only 3 (11.1%) of the 27 specimens exhibited  $\beta$ -catenin nuclear staining positive when AR was undetectable indicating that more nuclear  $\beta$ -catenin was present in AR-positive nuclei in CRPC tissues. Rajan et al. [35] detected  $\beta$ -catenin protein over-expression in 16 CRPC of 29 matched pairs of hormone-naïve PCa (HNPC) and CRPC; they also found a statistically significant correlation between  $\beta$ -catenin and nuclear AR protein expression in CRPC but not in HNPC. Chen et al. [43] observed 55% (34 out of 62) of primary prostate and 85% (20 out of 23) of prostate carcinoma metastases to lymph nodes and bone specimens with cytoplasmic and nuclear  $\beta$ -catenin expression, respectively. Additionally, Aaltomaa et al. [44] showed that only 18% (39 out of 186) of prostate cancer specimens from radical prostatectomy were positive nuclear  $\beta$ -catenin. Finally, Jung et al. [45] reported that ADT-treated patients who exhibited short times to PSA progression expressed higher levels of MMP-7. The expression of cytoplasmic  $\beta$ -catenin, MMP-7, and AR was positively correlated.

In the above section, we summarized studies that reported increased expression of nuclear  $\beta$ -catenin in CRPC; however, there were other groups that observed an opposite trend. Assikis et al. [46] examined  $\beta$ -catenin expression on a tissue microarray from 16 patients who underwent salvage surgery for symptomatic, locally aggressive androgen-independent prostate cancer and found no nuclear  $\beta$ -catenin expression in these specimens. Whitaker et al. [47] also examined for nuclear  $\beta$ -catenin staining in

17 specimens from patients before hormone therapy and 13 from patients after hormone therapy, and also found no significant differences in the nuclear  $\beta$ -catenin staining between hormone sensitive and hormone relapsed tissues. In prostate cancer specimens

that were most likely from hormone naïve patients, Bismar et al. did not detect any nuclear  $\beta$ -catenin staining in 101 prostatic adenocarcinomas, including 72 acinar and 29 ductal, and 16 cases of high-grade prostatic intraepithelial neoplasia (HPIN) using identical immunostaining procedures [48]. Membranous  $\beta$ -catenin act primarily as a cell adhesion molecule. The loss of membranous  $\beta$ -catenin in a small fraction of prostatic adenocarcinomas with higher Gleason scores was found in this study compared to normal prostatic epithelium. This result suggests a differential mechanism of  $\beta$ -catenin from its role as a cofactor for TCF/LEF or AR. Jaggi et al. [49] also examined 17 samples of prostate cancer specimens and found a significant down-regulation of membranous  $\beta$ -catenin expression in prostate cancer compared to benign prostatic glands and an association with increasing Gleason grade ( $p = 0.025$ ). In a prostate cancer prognosis study Horvath et al. [50] showed 64% (149 out of 232) of prostate cancer specimens with more than 10% of cells expressing nuclear  $\beta$ -catenin. However, those patients who had less than 10% of cells expressing  $\beta$ -catenin in the nucleus had decreased biochemical relapse-free survival times. In this study only 17.7% (41 cases) of these prostate cancer specimens were from patients with androgen deprivation therapy, therefore, this study did not separate hormone treatment naïve specimens from CRPC specimens.

In summary, the evidence suggests that there may be a role for nuclear localized  $\beta$ -catenin in CRPC specimens. However, the results remain conflicting. Perhaps the sample sizes and variations in the specimen processing and immunohistochemical staining methods may be contributing to the variations in the reported results



**Figure 1.** Overview of the Wnt signaling pathway. In the “Wnt-Off” state, Wnt/receptor interactions are interrupted by secreted Wnt antagonists, including sFRPs, DKKs and WIF1; and  $\beta$ -catenin is degraded by the formation of the “destruction complex” consisting of APC protein, Axin and others. In the “Wnt-On” state, Wnts are lipid modified by the acyl transferase porcupine in the endoplasmic reticulum, and act in an autocrine and paracrine fashion. The Wnts form a complex with Frizzled receptor and coreceptors LRP5/LRP6. Upon receptor activation, the “destruction complex” which includes APC, Axin and others is inhibited thereby blocking  $\beta$ -catenin phosphorylation for degradation. This inhibition results in cytoplasmic  $\beta$ -catenin stabilization and accumulation which facilitates its translocation into the nucleus. Nuclear  $\beta$ -catenin acts as a transcriptional co-activator for LEF1/TCF, leading gene transcription of Wnt target genes, such as JUN, Cyclin-D1, and MMP7. In addition, Wnts bind to tyrosine-protein kinase transmembrane receptors ROR2 and RYK to activate other non-canonical planar cell polarity, the Wnt/JNK and the Wnt/Calcium pathways.

with respect to  $\beta$ -catenin nuclear localization in CRPC.

#### $\beta$ -catenin and androgen receptor interaction

$\beta$ -Catenin contains 12 armadillo repeats in a highly conserved central region of the protein [33]. These armadillo repeats not only form a single structural unit to provide the interaction sites with APC, E-cadherin, and TCF/LEFs, but also can adopt an  $\alpha$ -helical conformation for nuclear receptor binding proteins [33]. Using a yeast two-hybrid system, Yang et al. [26] demonstrated that  $\beta$ -catenin preferentially and directly bound to the ligand binding domain of AR in the presence of dihydrotestosterone (DHT) over several other steroid hormone receptors which included estrogen receptor  $\alpha$ ,

progesterone receptor  $\beta$ , and glucocorticoid receptor. This study indicated that the NH(2) terminus and the first 6 armadillo repeats of  $\beta$ -catenin were required components for the AR interaction. The interaction between  $\beta$ -catenin and AR was further confirmed by several other studies showing that  $\beta$ -catenin bound to the activation function 2 region of the AR ligand binding domain and modulated the transcriptional effects of the transcriptional intermediary factor 2 (TIF2) and the AR N-terminal domain. Importantly, a single AR lysine (K720) has been shown to be necessary for the AR/ $\beta$ -catenin and TIF2 interactions [25, 30, 33].

The interactions between  $\beta$ -catenin and AR can be modulated by other cofactors through different signaling pathways in prostate cancer cells



as well.  $\beta$ -Catenin interacts with AR in close proximity to the binding groove for p160 coactivators such as TIF2/glucocorticoid receptor interacting protein-1 (GRIP1) [51-54]. TIF2/GRIP1 is one of the three p160 primary coactivator proteins, which serves as a scaffold to recruit a variety of secondary coactivators, including the protein acetyltransferases p300, CBP, and coactivator-associated arginine methyltransferase (CARM1). p300/CBP and CARM1 are recruited by the p160 complex to remodel chromatin through acetylation and methylation of histones and then functions in synergy with  $\beta$ -catenin as coactivators for AR and TCF/LEFs [53, 54]. The methyltransferase activity of CARM1 has also been shown to be necessary for its synergistic coactivator function with  $\beta$ -catenin to activate AR mediated transcription [53].


ICAT ( $\beta$ -catenin-interacting protein 1), an inhibitor of  $\beta$ -catenin and TCF, can inhibit the canonical Wnt/ $\beta$ -catenin signaling pathway by binding to  $\beta$ -catenin [27]. Expression of ICAT was observed in human prostate cancer tissues and found to be elevated in xenograft tumors in castrated mice [27]. Zhou et al. [27] showed that ICAT and AR can form a ternary complex with  $\beta$ -catenin and stabilize the  $\beta$ -catenin-AR complex, which resulted in enhanced AR-mediated transcription and cell growth. The DEAD box RNA helicase p68 (Ddx5) is often overexpressed in prostate cancer tissues compared with benign tissue and studies have shown that Ddx5 is also a transcriptional coactivator of AR [55]. Interestingly, Clark et al. [56] demonstrated that the interaction between Ddx5 and  $\beta$ -catenin required the presence of androgens in androgen-sensitive LNCaP cells as well as other cell lines such as LNCaP AI (a CRPC derivative of LNCaP cell line) when the cells are grown in the absence of androgen. Therefore, the function of Ddx5 was shown to be required for recruitment of AR and  $\beta$ -catenin to the promoter regions of androgen responsive genes for AR mediated transcription.

An AR variant [N-terminal truncated isoform of AR (AR45)], with an altered N-terminal domain with a replacement by a unique, short, seven amino-acid-long stretch, has been identified [57]. Overexpression of AR45 was shown to interact with the full-length AR and inhibit AR transcriptional activity and inhibit the growth of LNCaP cells [58]. However, under the conditions of  $\beta$ -catenin overexpression, AR45 incre-

ased dihydrotestosterone mediated AR promoter activity [58]. This result suggested that AR splicing variants may have differential effect on prostate cancer cell growth under  $\beta$ -catenin overexpression or overactivity.

Recent success in clinical trials of second generation of the anti-androgen drugs Abiraterone and Enzalutamide strongly support that the aberrant activation of the AR pathway in the absence of high circulating levels of androgen plays a critical role in CRPC [7, 8]. It has been suggested that AR signaling in CRPC is sustained by development of AR amplification, mutation, alternate splicing, and several alternative molecular mechanisms [6, 10]. When prostate cancer cells have been adapted to the low androgen environment,  $\beta$ -catenin has been shown to act as a coactivator of AR to enhance AR transcriptional activity not only in the presence of DHT, but also in the presence of androstenedione, a weaker adrenal androgen remaining present in CRPC patients [26, 30, 33].  $\beta$ -Catenin is also one of the three AR coactivators (other two AR specific coactivators are ARA70 and ARA55) that can enhance AR transcriptional activity in LNCaP cells when treated with 17 $\beta$ -estradiol [26, 30, 33]. In addition,  $\beta$ -catenin can function as a coactivator with altered ARs with mutations W741C and T877A in prostate cancer cell lines [33]. These AR mutations were detected in CRPC patients that have been treated with bicalutamide leading to the W741C mutation and also in CRPC patients with lymph node metastatic lesions containing the T877A mutation [33]. In rodent studies, Chesire et al. [22] reported that castrated mice receiving androgen treatment exhibited nuclear co-localization of AR and  $\beta$ -catenin in normal prostatic epithelium. Nuclear  $\beta$ -catenin localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate from androgen deprivation induced regression. Furthermore, Wang et al. [20] observed increased expression and nuclear colocalization of AR and  $\beta$ -catenin as well as the interaction between endogenous AR and  $\beta$ -catenin in CRPC from castrated mice. However, they found no interaction or colocalization of AR and  $\beta$ -catenin in xenografts from noncastrated mice. Mutations of  $\beta$ -catenin are uncommon in prostate cancer (< 5%) [59, 60].

Taken together, these results suggested that  $\beta$ -catenin plays an integral role in formation of the androgen-receptor transcriptional complex



**Figure 2.** A simplified and hypothetical relationship between Wnt and AR signaling during prostate cancer development and progression. In the normal prostate, Wnt signaling maintains prostate progenitor cells through regulation of Wnt target gene transcription, whereas AR signaling only functions in secretory luminal epithelial cells. In hormone treatment naïve prostate cancer cells, Wnt signaling promotes transcription of AR target genes, while androgen signaling inhibits the transcription of Wnt target genes. In CRPC, AR and Wnt signaling reinforces each other to elicit specific target genes for promoting androgen-independent growth and progression.

in CRPC. Based on available information, we proposed a simplified relationship between Wnt and AR signaling during prostate cancer development and progression as summarized in **Figure 2**. AR and Wnt signaling may reinforce each other to elicit specific target genes for promoting androgen-independent growth and progression. As such, β-catenin/AR interactions could have distinct clinical relevance and be a potential therapeutic target for treatment of CRPC, especially working best at low androgens.

#### The cross-talk between β-catenin and multiple pathways in prostate cancer

Nuclear β-catenin can also arise through other mechanisms besides alterations in the canonical Wnt signaling pathway. In this section we consider examples of the accumulation of β-catenin through other mechanisms. Constitutive protein kinase B (also known as AKT) activation in prostate cancer due to loss of PTEN can inhibit GSK-3β activity leading to stabilization and nuclear accumulation of β-catenin [61]. Liu et al. [62] demonstrated that addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and phosphorylation of glycogen synthase kinase-3β (GSK-3β) with subsequent cytoplasmic accumulation of β-catenin. This is followed by nuclear translocation, formation of the β-catenin/AR complex and increased AR transcriptional activity in LNCaP cells. Paradoxically,

in neuronal cells, Pawlowski et al. [63] demonstrated that ligand-bound AR promoted the accumulation of β-catenin in the nucleus. The nuclear co-localization of AR and β-catenin was independent of the GSK-3β, p42/44 ERK mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways. Other groups have shown that GSK-3β can phosphorylate AR and suppress its ability to activate transcription under certain conditions. Wnt pathway activation can stimulate Akt activity which promotes an MDM-2-mediated degradation process that reduces AR protein levels in Wnt-stimulated prostate cancer cells [64, 65].

Adenomatous polyposis coli (APC) is a major regulator of β-catenin protein level through phosphorylation of β-catenin which signals the degradation of β-catenin. Inactivation of APC gene by hypermethylation was detected in prostate cancer but not in normal prostate tissues [66, 67] thereby favoring the accumulation of β-catenin. However, Mulholland et al. [68] reported that AR can promote β-catenin nuclear translocation independently of APC. Pin1 is a peptidyl-prolyl cis/trans isomerase that stabilizes β-catenin by inhibiting its binding to the APC gene product and subsequent GSK-3β-dependent degradation. The expression of Pin1 in radical prostatectomy specimens is strongly correlated with the incidence of recurrence and metastasis [69]. Pin1 stabilizes β-catenin and abrogates the β-catenin and AR

interaction, leading to increased  $\beta$ -catenin/TCF-4 signaling and increased expression of the WNT target genes c-Myc and TCF-4 itself [69]. The result is exclusive to PTEN-deficient LNCaP cells. Protocadherin-PC, localized on the human Y chromosome, was shown to be selectively expressed in apoptosis-resistant and hormone-resistant human prostate cancer cells and tissues [70]. Expression of cytoplasmic protocadherin-PC can induce expression of Wnt target genes through interacting and stabilizing  $\beta$ -catenin [70]. These mechanisms illustrate different means of directing gene regulation involving  $\beta$ -catenin.

Hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) is a transcription factor that plays an essential role in cellular response to hypoxia. HIF-1 $\alpha$  is known to enhance  $\beta$ -catenin activated AR transactivation in hypoxia [71]. During cellular hypoxia, increased expression of complexes composed of HIF-1 $\alpha$ , AR and  $\beta$ -catenin in the nucleus were observed and activated androgen responsive genes. Knockdown of HIF-1 $\alpha$  attenuated the recruitment of AR and  $\beta$ -catenin to the androgen response elements (AREs) and deactivated activation of androgen-responsive genes [71].  $\beta$ -Catenin can also interact with FOXO transcriptional factors in response to oxidative stress to promote cells exit from the cell cycle and entry into cell quiescence [72]. FOXA1 was shown to be overexpressed in advanced prostate cancer and metastases, and over expression of FOXA1 led to enrichment of the Wnt signaling pathway [73]. Heterogeneous nuclear ribonucleoprotein K (HnRNP K) was also found to be overexpressed in prostate cancer tissues and overexpression of HnRNP K positively associated with high Gleason score and poor prognosis [74, 75]. HnRNP K can bind to the  $\beta$ -catenin/TCF-4 complex for regulation of pre-mRNA splicing and some types of alternative splicing have been suggested to promote prostate cancer progression [74, 75]. Finally,  $\beta$ -catenin can also influence the metastatic potential of prostate cancer cells by suppression of transcription of a metastasis suppressor, KAI1, through formation of a  $\beta$ -catenin-reptin chromatin remodeling complex [76].

### TCF family members in prostate cancer

Despite extensive research, the crosstalks between AR and Wnt/ $\beta$ -catenin signaling path-

ways remain complex and conflicting. The canonical Wnt pathway is mediated by TCF/LEF-1 transcription factor family members which include TCF-1, TCF-3, TCF-4 and LEF-1 [38]. The human AR gene itself has been shown to be a Wnt target gene [65]. Activation of Wnt/ $\beta$ -catenin signaling by Wnt stimulation can increase AR expression via TCF/LEF-1-binding sites on the AR promoter, leading to upregulation of AR target genes [65]. On the contrary, AR can also compete with TCF/LEF-1 for  $\beta$ -catenin binding and thus inhibit TCF/LEF-1 mediated transcription [77]. Chesire et al. showed that anti-androgens alleviated the AR mediated suppression of TCF transcriptional activity and activation of TCF/LEF-1 inhibited the expression of AR-regulated genes [40, 78]. Other studies demonstrated that there is a direct interaction between the AR DNA binding domain and TCF-4 and that endogenous AR is bound to the TCF responsive element in the MYC promoter [79]. Ectopic expression of TCF-4 by transfection repressed the transcriptional activity of full-length AR, which was only partially attenuated by  $\beta$ -catenin transfection [79]. AR activator of 55 kDa (ARA-55), also named hydrogen peroxide-induced clone 5 (HIC-5), belongs to the paxillin family of LIM proteins and is also a component of the focal adhesion complex [80, 81]. ARA-55 can bind to AR resulting in an increase of AR transcriptional activity and in turn alter ligand specificity of AR [80, 81]. The LIM domain-containing C-terminal half of ARA-55 binds to a conserved alternatively spliced exon in LEF/TCF transcription factor and functions as negative regulator of a subset of LEF/TCF family members [80, 81]. Possible function significance of these different LEF/TCF transcription complexes requires further investigation.

The Lymphoid Enhancer Factor 1 (LEF-1) is another member of TCF/LEF family and also a Wnt target gene [82]. Li and Lee et al. reported that *LEF1* mRNA levels are up 100 fold higher in LNCaP AI cells (a CRPC derivative of LNCaP cells) compared to the parental LNCaP cells as determined by a microarray gene expression profiling analysis [82]. LEF-1 expression was associated with increased cell proliferation, migration, and invasion as well as AR expression [82, 83]. LEF-1 is usually expressed in the basal epithelial layer of the urogenital sinus in the human fetal prostate and in the urogenital

mesenchyme and the basal epithelial layer of the urogenital sinus in mouse prostate development. The survival of LEF-1-expressing basal cells was not affected by treatment with the anti-androgen bicalutamide. Moreover LEF-1 can repopulate the luminal compartment following bicalutamide-induced regression of branching morphogenesis in the absence of androgen signaling [84]. This result suggested that LEF-1 may be involved in producing an androgen-independent population of prostate progenitors. TMPRSS2-ERG fusion protein has recently been shown to be reactivated in CRPC [85, 86]. Wu et al. [87] provided evidence that LEF-1 is a critical transcriptional target of the ETS-family transcription factor ERG and that LEF-1 expression is selectively upregulated in TMPRSS2-ERG fusion positive prostate cancer as observed by microarray profiling analysis. The combined results suggested that LEF-1 and Wnt signaling may provide a good novel targets for treatment of prostate cancer patients with TMPRSS2-ERG fusion expression.

### **Expression profiling and second generation sequencing identifies activation of the Wnt pathway in CRPC**

Recent gene expression profiling analyses have allowed for the identification specific molecular signatures that are associated with CRPC. Wang et al. [20] performed affymetrix genechip analysis using LNCaP xenografts and hollow fiber models to identify global changes in gene expression profiling associated with CRPC. They found that the Wnt/ $\beta$ -catenin signaling pathway was one of the major pathways activated in CRPC. Rajan et al. [35] performed RNA sequencing (RNA-seq) profiling on tumour-rich, targeted prostatic biopsies from 7 patients with locally advanced or metastatic prostate cancer before and approximately 22 weeks after ADT. The results showed that 29 (e.g. FZD4, FZD7, JUN, and MMP7) out of 150 genes in the Wnt signalling pathway were upregulated after ADT, which was the top pathway with significantly upregulated genes. In addition, 14 of these upregulated genes were reported in previously published studies on ADT-driven gene expression changes [88, 89]. These data suggested that the Wnt signaling pathway is predominantly upregulated in CRPC.

By using whole-exome sequencing technology to compare castration-resistant and androgen-

sensitive matched pairs of prostate cancer xenografts derived from the same site of origin, Kumar et al. [90] found that 86 gene mutations were unique to CRPCs. Among them, there was a significant enrichment of mutations in the components of the Wnt pathway in CRPC tumors, including FZD6, GSK3B and WNT6. Furthermore, Grasso et al. [34] performed whole-exome sequencing on 50 metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naïve, high-grade localized prostate cancers. They also identified components of the Wnt signaling pathway to be significantly mutated (57 somatic mutations in 38 samples) in CRPC, on the other hand, Wnt pathway alterations were virtually absent in hormone naïve primary prostate cancer. In conclusion, these results suggested that mutations in the Wnt pathway likely emerge during progression or the development of resistance after ADT in prostate cancer.

### **Wnt paracrine signaling from prostatic stroma affects prostate epithelium in the settings of resistance to ADT or chemotherapy**

There are emerging studies indicating that Wnt paracrine signaling from neighboring prostatic stroma cells could affect prostate epithelium during prostate cancer initiation and development of resistance to ADT or chemotherapy [36, 37, 91]. Using a tissue recombination method, Zong et al. [92] showed that high-mobility group AT-hook 2 (HMGA2) overexpressing urogenital sinus mesenchymal (UGSM) promoted multifocal prostatic intraepithelial neoplasia (PIN) in the neighboring naïve epithelium. Co-overexpression of HMGA2 and AR in UGSM cells synergistically induced poorly differentiated prostate adenocarcinoma. Wnt ligands (*i.e.* WNT2, 4 and 9A) were shown to be the major paracrine factors from HMGA2 overexpressing UGSM. HMGA2-induced PIN formation was strongly inhibited by overexpression of the Wnt antagonists DKK1 and SFRP2, both secreted products. This study suggested that Wnt paracrine signaling may play an important stroma contribution to prostate cancer initiation and progression. In a related study, Li et al. [36] demonstrated that stroma-specific knockout mice for the TGF- $\beta$  type II receptor expression (*Tgfr2<sup>fspKO</sup>*) increased the expression of Wnt3a to promote PIN formation and tumorigenesis, and that systemic treatment with Wnt3a neu-



tralizing antibodies inhibited growth of LNCaP/Tgfr2<sup>fspKO</sup> xenografts. Placencio et al. [91] from the same group further demonstrated that the prostates of Tgfr2<sup>fspKO</sup> mice had constitutively active Wnt signaling regardless of androgen status. The prostates of Tgfr2<sup>fspKO</sup> as well as Tgfr2<sup>fspKO</sup> prostatic stromal cells/wild-type or SV40 large T antigen expressing epithelia recombinants were resistant to androgen deprivation-mediated regression. These results suggested that the paracrine Wnt signaling from Tgfr2<sup>fspKO</sup> prostate stroma cells not only facilitated the progression of PIN lesions to adenocarcinoma, but also conferred resistance to the epithelial component to androgen deprivation.

Liu et al. [93] studied the effect of dihydrotestosterone (DHT) on the interactions between preosteoblasts MC3T3 cells and bone metastasis cell line MDA-PCa-2b. They found that DHT exerted more potent growth stimulating effect on MDA-PCa-2b cells via upregulation of Wnt activity in bone cells. The effect was enhanced when the prostate cancer cells were cocultured with preosteoblasts compared to DHT treatment of MDA-PCa-2b cells alone. The enhanced growth of MDA-PCa-2b cells by DHT in this coculture experiment can be blocked by exogenous Wnt antagonists such as DKK-1 and SFRP-1 recombinant proteins. This result indicated a potential role of paracrine Wnt factors from bone cells on prostate cancer cell growth at bone metastatic sites. Sun et al. [37] showed that mitoxantrone and docetaxel therapy induced expression of stromal WNT16B and the elevated expression levels of WNT16B in prostatectomy tissue samples were associated with high risk of cancer recurrence. WNT16B expression in the stroma can also promote epithelial-to-mesenchymal transition (EMT) to increase tumor invasiveness and tumor growth. These findings provided a new mechanism of acquired resistance to chemotherapy drugs that is based on the properties of the tumor microenvironment.

### Wnt ligands, receptors, secreted Wnt antagonists in prostate cancer

There is accumulating data showing overexpression of Wnt ligands and FZD receptors in prostate cancer potentially form autocrine or paracrine loops that support prostate cancer progression. The expression of WNT1 was detected in prostate cancer cells, tissues,

lymph nodes and bone metastases, and the expression positively correlated with high Gleason scores and high serum PSA levels [48]. Elevated expression of Wnt agonists: WNT5A, WNT2, WNT6, and WNT11 have also been detected in prostate cancer tissues versus normal samples [23, 94-96]. Wnt agonists like WNT5A and WNT11 can induce the non-canonical Wnt pathway (e.g. through the JNK pathway) [23]. Interestingly, WNT11 inhibited androgen-dependent but not androgen-independent prostate cancer cell growth [23]; whereas, WNT3A stimulation enhanced AR activity and prostate cancer cell growth in presence of low androgen levels [23]. WNT11 can be regulated by androgens and WNT11 can induce expression of neuroendocrine differentiation markers NSE and ASCL1 as well as promote cell invasion [97]. WNT5A can also activate Wnt/Ca<sup>2+</sup> pathway via CaMKII [98]. Yamamoto et al. [99] showed that WNT5A overexpression enhanced cell invasion in prostate cancer cell lines (*i.e.* PC3 cells), which required the expression of Wnt receptors Frizzled-2 and Ror2. Abnormal expression of WNT5A was positively correlated with high Gleason scores and biochemical relapse of prostate cancer [99]. Using transgenic mouse models, Takahashi et al. [100] demonstrated that the introduction of the AR with the T877A mutation into epithelial cells of the TRAMP mice resulted in an accelerated onset of tumor formation and tumor growth, moreover, this effect of the AR T877A mutation can be blocked by crossing Wnt-5a haploinsufficient mice with the TRAMP mice. In contrast, Syed Khaja et al. [101] reported that overexpression of WNT5A protein in patients with localized prostate cancer was shown to predict a favorable outcome after surgery. Recombinant WNT5A treatment of 22Rv1 and DU145 cells resulted in a decreased invasion [101]. These results suggested that Wnts may act differentially in a context-dependent manner during prostate cancer progression.

There are several Wnt receptors that are expressed in normal prostate tissues which includes FZD-1, -4, -6, and -10. Out of these receptors, expression of FZD-4 and FZD-6 were found to be increased in prostate tumors [102-105]. Gupta et al. [106] reported that ERG oncogenic transcriptional factor regulated the expression of FZD-4, which mediated epithelial-to-mesenchymal transition in prostate cancer.

Secreted Wnt antagonists, which include the secreted frizzled-related protein (sFRP) family, Dickkopf (DKK) family, and Wnt inhibitory factor-1 (WIF-1), are negative modulators of Wnt signaling [107-109]. Wnts bind to FZDs via cysteine-rich domain (CRD) sequence with high affinity. Expression of CRD alone can inhibit Wnt/ $\beta$ -catenin signaling [107]. All sFRPs contain a CRD sequence and can inhibit Wnt signaling either by sequestering Wnt ligands or by forming nonfunctional complexes with Frizzled receptors [107]. The Dkk family proteins include DKK-1, -2, -3, and -4 in humans [108]. DKK-1 inhibits Wnt signaling by disrupting the binding of LRP6 to the Wnt/FZD ligand-receptor complex [108]. Although WIF-1 does not share any sequence similarity with the CRD sequence of FZDs and sFRPs, it can also bind to Wnts and inhibit signaling [109]. Down-regulation of sFRPs, DKKs and WIF-1 by gene deletion or promoter hypermethylation are frequently detected in many human cancers including prostate cancer [110-114], suggesting their possible role as tumor suppressors. Endogenous Dkk-3 was found to be required to limit cell proliferation both in the developing mouse prostate and in 3D cultures of human prostate epithelial cells [115]. DKK-3 was further shown to regulate the response of normal prostate epithelial cells to transforming growth factor- $\beta$  (TGF- $\beta$ ) [116]. These studies are consistent with a model in which DKK-3 is required by normal cells to prevent the TGF- $\beta$ -dependent switch from tumor suppressor to tumor promoter. In contrast, DKK-1 was shown to promote tumor growth and prostate cancer progression in part by suppression of p21 (CIP1/WAF1) through a mechanism independent of canonical Wnt signaling [117]. DKK-1 also inhibited Wnt induced osteoblastic activity [118]. DKK-1 appears to play a role in parathyroid hormone related protein (PTHrP) induced osteolytic activity and in transition from osteoblastic to osteolytic bone lesions [119]. The sFRP family member sFRP1 was also found to be down-regulated both in prostate cancer tissues and prostate cancer cell lines. SFRP1 can function as a negative regulator of the AR [120]. However, this effect of sFRP1 was not associated with Wnt inhibition [120]. Joesting et al. [121] found that sFRP1 was overexpressed in prostate cancer stromal cells and overexpression of sFRP1 activated JNK pathway, but not the canonical Wnt pathway. Horvath et al. [50] reported that

sFRP4 overexpression can decrease cell proliferation, anchorage-independent growth, and invasiveness in PC3 cells. SFRP3/FRZB was the first identified secreted Wnt antagonist during studies of the Spemann's organizer of *Xenopus* [122]. Our group has shown that expression of sFRP3/FRZB or WIF-1 in a CRPC cell line PC3 caused a reversal of epithelial-to-mesenchymal transition and inhibition of tumor growth by inhibition of canonical Wnt pathway [123, 124]. Taken together, these results suggested that the role of Wnt ligands and secreted antagonists work in context-dependent manner in different types of cells or by varied ligand-receptor interactions. Wnt ligands and receptors appear to be important in CRPC.

### Wnt signaling in disease models of CRPC

In transgenic mouse models, conditionally deleted exon3 of  $\beta$ -catenin resulted in production of high-grade PIN (HG-PIN) and induction of Foxa2 re-expression in the adult mouse prostate through Wnt/ $\beta$ -catenin signaling as well as promoting prostate growth even under the conditions of androgen deprivation [125]. In mouse models with the SV40 large T-antigen, which inactivates p53 and Rb [126], or in mice expressing mutated K-ras and form invasive carcinoma [127], or in mice with loss of PTEN expression [128],  $\beta$ -catenin overexpression can promote highly invasive prostate cancer and squamous metaplasia, even in the absence of androgens. These findings provided strong evidence for a critical role of the Wnt/ $\beta$ -catenin signaling in prostate cancer development and progression.

In xenograft mouse models, H2 relaxin (RLN2) was shown to facilitate castrate-resistant growth of prostate cancer cells through AKT phosphorylation-mediated activation of both the Wnt/ $\beta$ -catenin and the AR pathway [129]. As mentioned before Hic-5/ARA55 is a co-factor for both TCF/LEFs and AR and can inhibit the Wnt/ $\beta$ -catenin pathway [36]. Overexpression of HIC-5/ARA55 in LNCaP cells can restore sensitivity of xenograft composed of LNCaP cells and Tgfbr2-KO fibroblasts to androgen deprivation-induced tumor regression [130]. In an orthotopic C4-2B CRPC xenograft mouse model, Placencio et al. [131] found that mesenchymal stem cells (MSCs) were recruited into tumor sites and were associated with enhanced tumor growth. The result occurs with

activation of Wnt signaling. When MSCs were used as a targeted delivery vector for the exogenously expressed sFRP2, tumor growth was reduced and the response to androgen deprivation was restored. These animal and tissue culture studies suggested that components of the Wnt signaling pathway may be involved in prostate cancer progression to more invasive phenotype and contributed to castration resistance.

### Therapeutic potentials of targeting Wnt/ $\beta$ -catenin in CRPC and future directions

Although, the results remain inconclusive,  $\beta$ -catenin nuclear localization as well as its co-localization with AR has been more frequently observed in CRPC compared to hormone naïve prostate cancer. Alterations in multiple signaling pathways, including PI3K/AKT, HIF-1 $\alpha$ , PIN1, APC gene silencing and more have been shown to cause nuclear localization of  $\beta$ -catenin and activation of Wnt signaling. Moreover,  $\beta$ -catenin acts as an AR co-factor to enhance androgen-stimulated AR transcriptional activation and increase sensitivity to low levels of androgens and to non-androgen ligands. As a result, the interaction between  $\beta$ -catenin and AR in CRPC may elicit specific target genes for promoting androgen-independent growth and progression. The next-generation sequencing technology (*i.e.* whole-exome and RNA sequencing) has revealed that the Wnt pathway is one of the top signaling pathways that were frequently mutated or genomically altered in lethal CRPC patients. Likewise, paracrine Wnt signaling also contributed to resistance to ADT after chemotherapy and androgen deprivation therapy.

In addition to high expression in cancer cells, Wnt/ $\beta$ -catenin signaling is highly activated in cancer stem cells (CSCs) [132]. Prostate CSCs are suggested to be resistant to androgen deprivation therapy and responsible for cancer recurrence [133]. Targeting CSCs by inhibition of the Wnt pathway may have the potential to reduce the self-renewal and aggressive behavior of prostate cancer [134]. As a proof of principle, Lee et al. [135] demonstrated that a novel compound that disrupts both  $\beta$ -catenin/TCF and  $\beta$ -catenin/AR protein interactions can inhibit prostate tumor growth in a xenograft model and also blocked bicalutamide-resistant sphere-forming cells. This study indicated the

potential of targeting the  $\beta$ -catenin/AR as a good treatment target for CRPC.

As described in this review, the Wnt signaling pathway plays a complex role in CRPC. Given the multiple important roles of Wnt signaling in CRPC, the Wnt signaling pathway can not be ignored as a source of therapeutic targets. Inhibition of the Wnt pathway would allow therapies to target not only epithelial cells but also stromal cells, as well as, CSCs, androgen-dependent, and androgen-independent prostate cancer cells. Future therapies for CRPC would most likely benefit from combination of both anti-androgens and Wnt inhibitors.

### Acknowledgements

We apologize for not being able to cite all of the publications in the field due to the limitations of the length of the review. NY is supported by DOD grant W81XWH-13-1-0257. XZ is supported by UCI ICTS pilot grant, DOD grant W81XWH-11-1-0312 and NIH grants R01CA122558 and R21CA152804.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Xiaolin Zi, Department of Urology, University of California, Irvine, 101 The City Drive South, Rt. 81 Bldg. 55 Rm. 302, Orange CA 92868, USA. Tel: 714-456-8316; Fax: 714-456-1786; E-mail: xzi@uci.edu

### References

- [1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; 63: 11-30.
- [2] Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. *In Vivo* 1994; 8: 439-43.
- [3] Lennernas B, Edgren M, Haggman M, Norlen BJ, Nilsson S. Postoperative radiotherapy after prostatectomy—a review. *Scand J Urol Nephrol* 2003; 37: 10-5.
- [4] Ahlering TE, Skarecky DW. Long-term outcome of detectable PSA levels after radical prostatectomy. *Prostate Cancer Prostatic Dis* 2005; 8: 163-6.
- [5] Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endo-

- crine therapy. *Urol Clin North Am* 1991; 18: 15-24.
- [6] Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene* 2013; 32: 5501-11.
- [7] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Lortol Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; 364: 1995-2005.
- [8] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AF-FIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; 367: 1187-1197.
- [9] Korpai M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). *Cancer Discov* 2013; 3: 1030-43.
- [10] Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. *Oncogene* 2013; [Epub ahead of print].
- [11] Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. *Proc Natl Acad Sci U S A* 2013; 110: 17492-7.
- [12] Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. NF- $\kappa$ B2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. *Mol Cancer Ther* 2013; 12: 1629-37.
- [13] Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH. A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509. *Cancer Discov* 2013; 3: 1020-9.
- [14] Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. *Cancer Res* 2013; 73: 483-9.
- [15] Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. *PLoS One* 2011; 6: e27970.
- [16] Colloca G. Role of androgens in abiraterone resistance. *J Clin Oncol* 2012; 30: 3561-2.
- [17] Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N. Abiraterone inhibits 3 $\beta$ -hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. *Clin Cancer Res* 2012; 18: 3571-9.
- [18] Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. *Clin Cancer Res* 2011; 17: 5913-25.
- [19] Polakis P. Wnt signaling in cancer. *Cold Spring Harb Perspect Biol* 2012; 4: 5.
- [20] Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. *Cancer Res* 2008; 68: 9918-27.
- [21] Schweizer L, Rizzo CA, Spire TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. *BMC Cell Biol* 2008; 9: 4.
- [22] Chesire DR and Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. *Endocr Relat Cancer* 2003; 10: 537-60.
- [23] Zhu H, Mazar M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. *Cancer Res* 2004; 64: 7918-26.
- [24] Verras M, Brown J, Li X, Nusse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. *Cancer Res* 2004; 64: 8860-6.
- [25] Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. *Cancer Res* 2000; 60: 4709-13.
- [26] Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking beta-catenin to androgen-signaling pathway. *J Biol Chem* 2002; 277: 11336-44.
- [27] Zhuo M, Zhu C, Sun J, Weis WI, Sun Z. The beta-catenin binding protein ICAT modulates an-



- drogen receptor activity. *Mol Endocrinol* 2011; 25: 1677-88.
- [28] Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. *Oncogene* 2008; 27: 499-505.
- [29] Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. *Cancer Res* 2007; 67: 5747-53.
- [30] Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. *Mol Endocrinol* 2004; 18: 2388-401.
- [31] Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. *J Biol Chem* 2003; 278: 30828-34.
- [32] Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of  $\beta$ -catenin signaling in androgen receptor-negative prostate cancer cells. *Clin Cancer Res* 2012; 18: 726-36.
- [33] Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. *Mol Cell Biol* 2003; 23: 1674-87.
- [34] Grasso CS, Wu YM, Robinson DR, Cao X, Dhannasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. *Nature* 2012; 487: 239-43.
- [35] Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenamin RM, Pedley ID, Leung HY. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. *Eur Urol* 2013; [Epub ahead of print].
- [36] Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. *Oncogene* 2008; 27: 7118-30.
- [37] Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. *Nat Med* 2012; 18: 1359-68.
- [38] Sprowl S, Waterman ML. Past visits present: TCF/LEFs partner with ATFs for  $\beta$ -catenin-independent activity. *PLoS Genet* 2013; 9: e1003745.
- [39] Gómez-Orte E, Sáenz-Narciso B, Moreno S, Cabello J. Multiple functions of the noncanonical Wnt pathway. *Trends Genet* 2013; 29: 545-53.
- [40] Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. *Oncogene* 2002; 21: 2679-94.
- [41] de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. *Clin Cancer Res* 2003; 9: 1801-7.
- [42] Patriarca C, Petrella D, Campo B, Colombo P, Giunta P, Parente M, Zucchini N, Mazzucchelli R, Montironi R. Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma. *Pathol Res Pract* 2003; 199: 659-65.
- [43] Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. *Cancer* 2004; 101: 1345-56.
- [44] Aaltomaa S, Lipponen P, Kärjä V, Lundstedt S, Lappi J, Kosma VM. The expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma. *Anticancer Res* 2004; 24: 2407-13.
- [45] Jung SJ, Oh S, Lee GT, Chung J, Min K, Yoon J, Kim W, Ryu DS, Kim IY, Kang DI. Clinical Significance of Wnt/ $\beta$ -Catenin Signalling and Androgen Receptor Expression in Prostate Cancer. *World J Mens Health* 2013; 31: 36-46.
- [46] Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. *Clin Cancer Res* 2004; 10: 6770-8.
- [47] Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. *Prostate* 2008; 68: 1196-205.
- [48] Bismar TA, Humphrey PA, Grignon DJ, Wang HL. Expression of beta-catenin in prostatic adenocarcinomas: A comparison with colorectal adenocarcinomas. *Am J Clin Pathol* 2004; 121: 557-563.

- [49] Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. *Urol Oncol* 2005; 23: 402-6.
- [50] Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. *Int J Cancer* 2005; 113: 415-22.
- [51] Song LN, Gelmann EP. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. *J Biol Chem* 2005; 280: 37853-67.
- [52] Yang CK, Kim JH, Li H, Stallcup MR. Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1. *J Biol Chem* 2006; 281: 3389-97.
- [53] Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM, Stallcup MR. Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. *J Biol Chem* 2002; 277: 26031-5.
- [54] Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. *Mol Cell Biol* 2004; 24: 10689-702.
- [55] Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. *Cancer Res* 2008; 68: 7938-7946.
- [56] Clark EL, Hadjimichael C, Temperley R, Barnard A, Fuller-Pace FV, Robson CN. p68/Ddx5 supports  $\beta$ -catenin & RNAP II during androgen receptor mediated transcription in prostate cancer. *PLoS One* 2013; 8: e54150.
- [57] Wu ZY, Chen K, Haendler B, McDonald TV, Bian JS. Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether- $\alpha$ -go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. *Endocrinology* 2008; 149: 5061-9.
- [58] Ahrens-Fath I, Politz O, Geserick C, Haendler B. Androgen receptor function is modulated by the tissue-specific AR45 variant. *FEBS J* 2005 Jan; 272: 74-84.
- [59] Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. *Cancer Res* 1998; 58: 2520-3.
- [60] Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. *Prostate* 2000; 45: 323-34.
- [61] Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3 $\beta$  inhibition and nuclear beta-catenin accumulation. *J Biol Chem* 2002; 277: 30935-41.
- [62] Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. *Oncogene* 2008; 27: 499-505.
- [63] Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. *J Biol Chem* 2002; 277: 20702-10.
- [64] Lin HK, Wang L, Hu YC, Altuwajiri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. *EMBO J* 2002; 21: 4037-48.
- [65] Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y, Buttyan R. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. *Oncogene* 2006; 25: 3436-44.
- [66] Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. *Clin Cancer Res* 2007; 13: 6122-9.
- [67] Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. *Clin Cancer Res* 2005; 11: 8321-5.
- [68] Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. *J Biol Chem* 2002; 277: 17933-43.
- [69] Chen SY, Wulf G, Zhou XZ, Rubin MA, Lu KP, Balk SP. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. *Mol Cell Biol* 2006; 26: 929-39.
- [70] Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC. Relaxin drives Wnt signaling through upregulation of

- PCDHY in prostate cancer. *Prostate* 2010; 70: 1134-45.
- [71] Mitani T, Harada N, Nakano Y, Inui H, Yamaji R. Coordinated action of hypoxia-inducible factor-1 $\alpha$  and  $\beta$ -catenin in androgen receptor signaling. *J Biol Chem* 2012; 287: 33594-606.
- [72] Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. *Science* 2005; 308: 1181-4.
- [73] Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. *Oncogene* 2013; [Epub ahead of print].
- [74] Sato S, Iidogawa M, Honda K, Fujii G, Kawashima H, Takekuma K, Hoshika A, Hirohashi S, Yamada T. beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. *Gastroenterology* 2005; 129: 1225-36.
- [75] Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C, Ferrari N. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/ $\beta$ -catenin signaling in prostate cancer cells. *Int J Cancer* 2012; 131: 582-90.
- [76] Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG, Baek SH. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. *Nature* 2005; 434: 921-6.
- [77] Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. *Oncogene* 2003; 22: 5602-13.
- [78] Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. *Oncogene* 2002; 21: 8453-69.
- [79] Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. *J Biol Chem* 2003; 278: 30828-34.
- [80] Ghogomu SM, van Venrooy S, Ritthaler M, Wedlich D, Gradl D. HIC-5 is a novel repressor of lymphoid enhancer factor/T-cell factor-driven transcription. *J Biol Chem* 2006; 281: 1755-64.
- [81] Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. *Oncogene* 2011; 30: 167-77.
- [82] Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. *Cancer Res* 2005 Jun 15; 65: 5263-71.
- [83] Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. *Cancer Res* 2009; 69: 3332-8.
- [84] Wu X, Daniels G, Shapiro E, Xu K, Huang H, Li Y, Logan S, Greco MA, Peng Y, Monaco ME, Melamed J, Lepor H, Grishina I, Lee P. LEF1 identifies androgen-independent epithelium in the developing prostate. *Mol Endocrinol* 2011; 25: 1018-26.
- [85] Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K. TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. *PLoS One* 2012; 7: e41668.
- [86] Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. *PLoS One* 2013; 8: e74671.
- [87] Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. *Cancer Res* 2013; 73: 6068-79.
- [88] Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am J Pathol* 2004; 164: 217-227.
- [89] Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLJ, Visakorpi T. Chemical castration and anti-androgens induce differential gene expression in prostate cancer. *J Pathol* 2012; 227: 336-345.
- [90] Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and

- lethal prostate cancers. *Proc Natl Acad Sci U S A* 2011; 108: 17087-92.
- [91] Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. *Cancer Res* 2008; 68: 4709-18.
- [92] Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK, Witte ON. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. *Proc Natl Acad Sci U S A* 2012; 109: E3395-404.
- [93] Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. *Cancer Res* 2007; 67: 5747-53.
- [94] Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. *Int J Oncol* 2001; 19: 1003-7.
- [95] Iozzo RV, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5A in human malignancy. *Cancer Res* 1995; 55: 3495-99.
- [96] Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. *Cancer Res* 2005; 65: 7554-60.
- [97] Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, Waxman J, Kypta RM. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. *Mol Cancer* 2010; 9: 55.
- [98] Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JR, Ahmed A. A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. *PLoS One* 2010; 5: e10456.
- [99] Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, Matsubara A, Yasui W, Kikuchi A. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. *Oncogene* 2010; 29: 2036-46.
- [100] Takahashi S, Watanabe T, Okada M, Inoue K, Ueda T, Takada I, Watabe T, Yamamoto Y, Fukuda T, Nakamura T, Akimoto C, Fujimura T, Hoshino M, Imai Y, Metzger D, Miyazono K, Minami Y, Chambon P, Kitamura T, Matsumoto T, Kato S. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. *Proc Natl Acad Sci U S A* 2011; 108: 4938-43.
- [101] Syed Khaja AS, Helczynski L, Edsjö A, Ehrnström R, Lindgren A, Ulmert D, Andersson T, Bjartell A. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. *PLoS One* 2011; 6: e26539.
- [102] Sagara N, Toda G, Hirai M, Terada M and Katoh M. Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. *Biochem Biophys Res Commun* 1998; 252: 117-122.
- [103] Kirikoshi H, Sagara N, Koike J, Tanaka K, Sekihara H, Hirai M, Katoh M. Molecular cloning and characterization of human Frizzled-4 on chromosome 11q14-q21. *Biochem Biophys Res Commun* 1999; 264: 955-961.
- [104] Tokuhara M, Hirai M, Atomi Y, Terada M and Katoh M. Molecular cloning of human Frizzled-6. *Biochem Biophys Res Commun* 1998; 243: 622-627.
- [105] Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. *J Pathol* 2003; 201: 204-12.
- [106] Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. *Cancer Res* 2010; 70: 6735-45.
- [107] Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. *Bioessays* 2002; 24: 811-20.
- [108] Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. *J Cell Sci* 2003; 116: 2627-34.
- [109] Hsieh JC, Kodjabachian L, Rebbert ML, Ratner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. *Nature* 1999; 398: 431-6.
- [110] Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* 2004; 36: 417-22.
- [111] Stoehr R, Wissmann C. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. *Lab Invest* 2004; 84: 465-78.
- [112] Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing



- tumor subtypes in two large populations of colorectal cancer patients. *Carcinogenesis* 2011; 32: 741-7.
- [113] Urakami S, Shiina H, Enokida H. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. *Clin Cancer Res* 2006; 12: 383-91.
- [114] Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. *Cancer Res* 2005; 65: 4218-27.
- [115] Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. *Oncogene* 2006; 25: 6528-37.
- [116] Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, Waxman J, Kypta R. Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF- $\beta$ /Smad signalling. *J Cell Sci* 2013; 126: 1858-67.
- [117] Hall CL, Zhang H, Baile S, Ljungman M, Kuhs-toss S, Keller ET. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. *Cancer Res* 2010; 70: 9916-26.
- [118] Thudi NK, Martin CK, Murahari S, Shu ST, Lannigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. *Prostate* 2011; 71: 615-25.
- [119] Zhang H, Yu C, Dai J, Keller JM, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of  $\beta$ -catenin activation of the DKK1 promoter in prostate cancer. *Oncogene* 2013; [Epub ahead of print].
- [120] Kawano Y, Diez S, Uysal-Onganer P, Darrington RS, Waxman J, Kypta RM. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer. *Br J Cancer* 2009; 100: 11650-74.
- [121] Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. *Cancer Res* 2005; 65: 10423-30.
- [122] Wang S, Krinks M, Lin K, Luyten FP, Moos M Jr. Frzb, a secreted protein expressed in the Spe-mann organizer, binds and inhibits Wnt-8. *Cell* 1997; 88: 757-66.
- [123] Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH. Expression of Frzb/se-creted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-indepen-dent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. *Cancer Res* 2005; 65: 9762-70.
- [124] Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH, Zi X. The Wnt inhibitory factor 1 resto-ration in prostate cancer cells was associated with reduced tumor growth, decreased capac-ity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. *Mol Cancer* 2010; 9: 162.
- [125] Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ. Ac-tivation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. *Prostate* 2009; 69: 249-262.
- [126] Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/beta-catenin activation promotes pros-tate tumor progression in a mouse model. *On-cogene* 2011; 30: 1868-1879.
- [127] Pearson HB, Pesses TJ, Clarke AR K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. *Cancer Res* 2009; 69: 94-101.
- [128] Francis JC, Thomsen MK, Taketo MM, Swain A.  $\beta$ -catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. *PLoS Genet* 2013; 9: e1003180.
- [129] Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gan-dour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF- $\kappa$ B inhibits H2 relaxin-mediated castrate-resis-tant growth of prostate cancer sublines and induces apoptosis. *Horm Cancer* 2011; 2: 224-38.
- [130] Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA. Epithelial Hic-5/ARA55 expression contributes to prostate tu-morigenesis and castrate responsiveness. *On-cogene* 2011 Jan 13; 30: 167-77.
- [131] Placencio VR, Li X, Sherrill TP, Fritz G, Bhow-mick NA. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. *PLoS One* 2010; 5: e12920.
- [132] Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. *Cell Res* 2009 Jun; 19: 683-97.
- [133] Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. *J Clin Invest* 2007; 117: 2044-50.
- [134] Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initia-tion. *Proc Natl Acad Sci U S A* 2010; 107: 2610-5.
- [135] Lee E, Madar A, David G, Garabedian MJ, Das-gupta R, Logan SK. Inhibition of androgen re-ceptor and  $\beta$ -catenin activity in prostate can-

## Wnt signaling and castration-resistant prostate cancer

- cer. *Proc Natl Acad Sci U S A* 2013; 110: 15710-5.
- [136] Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. *Int J Cancer* 2013; 132: 1771-80.
- [137] Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Katiyar S, Crosariol M, Chen K, Wang M, Quong AA, Lisanti MP, Ertel A, Pestell RG. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. *Cancer Res* 2014 Jan 15; 74: 508-19.